P&G Acquires Premium Wellness Brand Thorne for $3.8 Billion

Procter & Gamble is acquiring health and supplement company Thorne in a deal valued at $3.8 billion, a strategic move aimed at expanding the consumer products giant's footprint in personal health and wellness.

While terms were omitted from the official release, P&G Chief Executive Officer Shailesh Jejurikar confirmed the $3.8 billion valuation during an interview on CNBC.

“We are really happy with the asset itself,” Jejurikar said. “It’s a really well-run operation, and it’s been around for a long time.” Thorne was founded in 1984.

Paul Gama, CEO of P&G Health Care, described the acquisition as a major milestone for P&G’s personal health care division, a category drawing close attention across global consumer healthcare as strategics recalibrate their portfolios—much like how Beiersdorf is restructuring its core business to align with evolving consumer demand.

“Consumer interest in self care, prevention, wellness and personalized health continues to grow, and Thorne strengthens our position in premium wellness with a trusted, science-backed brand that complements our existing portfolio,” Gama said.

Colin Watts, CEO of Thorne, added: “For more than 40 years, Thorne has earned the trust of health care practitioners, consumers and partners by putting science, quality and the people we serve at the center of every decision. As we looked to the future, we kept coming back to one question: What will best position Thorne to continue fulfilling its mission? We believe P&G is the right partner to help us expand our impact while staying true to the values and standards that have always defined Thorne.”

The acquisition, in which P&G will purchase Thorne from private equity firm L Catterton’s Flagship Fund, is expected to close later this year subject to regulatory approvals. While independent wellness brands often explore how debt financing can fuel retail growth, established institutional targets like Thorne give multinational strategics immediate access to clinical authority and loyal consumer bases.

P&G shares rose 1.5% to $147.20 following the announcement.